Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24775175 | 1.00 | SMN1; SMN2 (0.49) | SMN1; SMN2HCRTR2HCRTR1HTR2AHTR2C | |
| SCHEMBL28259677 | 0.92 | HTR2A (0.47) | SMN1; SMN2HCRTR2HCRTR1HTR2AHTR2C | |
| SCHEMBL24774754 | 0.89 | HTR2C (0.47) | SMN1; SMN2HCRTR2HCRTR1HTR2CHTR2B | |
| SCHEMBL24774522 | 0.85 | HTR2A (0.39) | SMN1; SMN2HCRTR2HCRTR1HTR2AALDH1A1 | |
| SCHEMBL24774523 | 0.84 | HSP90AA1 (0.36) | SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL24775174 | 0.84 | HSP90AA1 (0.47) | HTR2CALDH1A1MEN1KMT2A | |
| SCHEMBL24775072 | 0.84 | HSP90AA1 (0.47) | HTR2CALDH1A1MEN1KMT2A | |
| SCHEMBL24775062 | 0.83 | HTR1B (0.45) | SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL23323111 | 0.81 | SMN1; SMN2 (0.52) | SMN1; SMN2HCRTR2HCRTR1HTR2AHTR2C | |
| SCHEMBL24774521 | 0.81 | CHRNA7 (0.44) | HCRTR2HCRTR1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002369-A1 | Bcl-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-01-05 | — | — | US | disclosed |
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | SMN1; SMN2 1818/4885HCRTR2 2324/4885HCRTR1 3806/4885 |
| US-20230002369-A1 | Bcl-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | SMN1; SMN2 1818/4885HCRTR2 2324/4885HCRTR1 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.